Literature DB >> 28420030

Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline.

Lars Aabakken1, Tom H Karlsen2, Jörg Albert3, Marianna Arvanitakis4, Olivier Chazouilleres5, Jean-Marc Dumonceau6, Martti Färkkilä7, Peter Fickert8, Gideon M Hirschfield9, Andrea Laghi10, Marco Marzioni11, Michael Fernandez4, Stephen P Pereira12, Jürgen Pohl13, Jan-Werner Poley14, Cyriel Y Ponsioen15, Christoph Schramm16, Fredrik Swahn17, Andrea Tringali18, Cesare Hassan19.   

Abstract

1 ESGE/EASL recommend that, as the primary diagnostic modality for PSC, magnetic resonance cholangiography (MRC) should be preferred over endoscopic retrograde cholangiopancreatography (ERCP).Moderate quality evidence, strong recommendation. 2 ESGE/EASL suggest that ERCP can be considered if MRC plus liver biopsy is equivocal or contraindicated in patients with persisting clinical suspicion of PSC. The risks of ERCP have to be weighed against the potential benefit with regard to surveillance and treatment recommendations.Low quality evidence, weak recommendation. 6 ESGE/EASL suggest that, in patients with an established diagnosis of PSC, MRC should be considered before therapeutic ERCP.Weak recommendation, low quality evidence. 7 ESGE/EASL suggest performing endoscopic treatment with concomitant ductal sampling (brush cytology, endobiliary biopsies) of suspected significant strictures identified at MRC in PSC patients who present with symptoms likely to improve following endoscopic treatment.Strong recommendation, low quality evidence. 9 ESGE/EASL recommend weighing the anticipated benefits of biliary papillotomy/sphincterotomy against its risks on a case-by-case basis.Strong recommendation, moderate quality evidence.Biliary papillotomy/sphincterotomy should be considered especially after difficult cannulation.Strong recommendation, low quality evidence. 16 ESGE/EASL suggest routine administration of prophylactic antibiotics before ERCP in patients with PSC.Strong recommendation, low quality evidence. 17 EASL/ESGE recommend that cholangiocarcinoma (CCA) should be suspected in any patient with worsening cholestasis, weight loss, raised serum CA19-9, and/or new or progressive dominant stricture, particularly with an associated enhancing mass lesion.Strong recommendation, moderate quality evidence. 19 ESGE/EASL recommend ductal sampling (brush cytology, endobiliary biopsies) as part of the initial investigation for the diagnosis and staging of suspected CCA in patients with PSC.Strong recommendation, high quality evidence. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28420030     DOI: 10.1055/s-0043-107029

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  42 in total

Review 1.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

2.  [Radiologic diagnosis of the gallbladder and bile ducts - part 2 : Acute and chronic cholecystitis, primary sclerosing cholangitis (PSC), benign and malignant masses of the biliary system].

Authors:  H Helmberger; B Kammer
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

3.  Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis.

Authors:  Laetitia Nguyen; Nora Cazzagon; Christophe Corpechot; Sanaâ El Mouhadi; Sara Lemoinne; Olivier Chazouillères; Lionel Arrivé
Journal:  Eur Radiol       Date:  2018-08-29       Impact factor: 5.315

Review 4.  [Surgical approach to benign bile duct alterations].

Authors:  A Alvanos; S Rademacher; A Hoffmeister; D Seehofer
Journal:  Chirurg       Date:  2020-01       Impact factor: 0.955

Review 5.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 6.  Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.

Authors:  Jawad Ahmad
Journal:  Hepatol Int       Date:  2018-11-14       Impact factor: 6.047

7.  Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography.

Authors:  Vilja Koskensalo; Andrea Tenca; Marianne Udd; Outi Lindström; Mia Rainio; Kalle Jokelainen; Leena Kylänpää; Martti Färkkilä
Journal:  United European Gastroenterol J       Date:  2020-03-08       Impact factor: 4.623

Review 8.  [Primary sclerosing cholangitis : Current diagnostics and treatment].

Authors:  T Liwinski; C Schramm
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

9.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

10.  Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies.

Authors:  Madi El-Haj; Dimitri Kanovitch; Yaron Ilan
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.